Cognito Therapeutics, a Cambridge, MA-based clinical-stage neurotechnology company, has raised $105 million in a Series C funding round led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital.
The round also saw participation from New Vintage, Apollo Health Ventures, and Benvolio Group, among others.
Read More:AgriPass Raises $7.5M in Seed Funding
The company plans to use the funds to expand the Spectris platform into more neurodegenerative disease areas through its network of brain health collaboratories, starting with the WVU Rockefeller Neuroscience Institute.
“This funding marks an important moment for our company and for patients and families looking for new Alzheimer’s treatments,” said Christian Howell, CEO of Cognito Therapeutics. “Spectris has the potential to be the first physician-prescribed, at-home therapy designed to protect brain function in people with Alzheimer’s. This investment will help us make the therapy available to those who need it most.”
Spectris™ is an investigational, physician-prescribed therapy for home use. It uses non-invasive visual and sound stimulation to activate connected brain networks. By stimulating the brain through natural sensory pathways, Spectris is being studied for its potential to help preserve memory, daily function, and brain health in people with Alzheimer’s disease.
“Expanding treatment options for Alzheimer’s patients through precision medicine is very important,” said Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). “New technologies like Cognito’s, which are non-invasive and easy to access, will play an important role in the future of Alzheimer’s care. In the future, treatments may combine medicines, lifestyle changes, and devices to better support each patient based on their individual risk.”
“Cognito brings together strong neuroscience research, clinical validation, advanced engineering, and a deep understanding of patient needs,” said Gerald Chan, Founder of Morningside Ventures and Chairman of Cognito’s Board. “Spectris could change how many neurodegenerative diseases are treated by bringing therapy into the home, reducing the burden on patients and caregivers, and reaching people worldwide. We are proud to continue supporting Cognito as it moves toward regulatory approval and wider clinical use.”
The HOPE pivotal study (NCT05637801) has completed enrollment, and initial results are expected later this year. Spectris™ is an investigational device and has not yet been approved by the U.S. Food and Drug Administration.
About Cognito Therapeutics
Founded in 2016, Cognito Therapeutics is a late-stage neurotechnology company developing neuroprotective therapies for people with central nervous system (CNS) disorders. Its lead product, Spectris™, is an at-home therapy platform that uses non-invasive sensory stimulation to activate connected brain networks. Early studies suggest that Spectris may help preserve memory and daily function and slow brain shrinkage in patients with mild to moderate Alzheimer’s disease.
Read More:Sage Raises $65M in Series C Funding
